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Abstract
Background: Implant-related infections are characterized by bacterial colonization and biofilm formation on the prosthesis.
Diabetes represents one of the risk factors that increase the chances of prosthetic infections because of related severe
peripheral vascular disease. Vasodilatation can be a therapeutic option to overcome diabetic vascular damages and increase
the local blood supply. In this study, the effect of a PGE1 vasodilator on the incidence of surgical infections in diabetic mice
was investigated.
Methodology: A S. aureus implant-related infection was induced in femurs of diabetic mice, then differently treated with a
third generation cephalosporin alone or associated with a PGE1 vasodilator. Variations in mouse body weight were
evaluated as index of animal welfare. The femurs were harvested after 28 days and underwent both qualitative and
quantitative analysis as micro-CT, histological and microbiological analyses.
Results: The analysis performed in this study demonstrated the increased host response to implant-related infection in
diabetic mice treated with the combination of a PGE1 and antibiotic. In this group, restrained signs of infections were
identified by micro-CT and histological analysis. On the other hand, the diabetic mice treated with the antibiotic alone
showed a severe infection and inability to successfully respond to the standard antimicrobial treatment.
Conclusions: The present study revealed interesting preliminary results in the use of a drug combination of antibiotic and
vasodilator to prevent implant-related Staphylococcus aureus infections in a diabetic mouse model.
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Introduction
Implant-related infection has been recently reported as,
respectively, the first and the third reason for failure of knee and
hip prosthesis in the U.S. [1,2]. Infection rates after revision
surgery are considerably higher (5–40%) than after primary
replacement [3].
Implant-related infections represent the 65% of orthopaedic
infections and they are characterized by bacterial colonization and
biofilm formation on the prosthetic implant and within the
contiguous tissues [4]. Bacteria within biofilm, in particular
Staphylococcus aureus, are extremely resistant to antibiotics and
persistent infections arise despite proper therapies [5]. Treatments
usually involve debridement procedures, surgical revisions and
long term antibiotic therapy. Nevertheless, some infections are not
entirely eradicated and lead to implant failure or loss [6].
Patient co-morbidities - diabetes, obesity, immunodeficiency
and vascular diseases – represent risk factors that increase the
chances of implant-related infections. In particular, diabetes alters
the tissue healing and induces a high susceptibility to infections
with risk of mortality [7]. Diabetes results in several disorders such
as peripheral neuropathy, vasculopathy and ischemia due to the
compromised granulocyte adherence [8,9]. Neuropathy and
angiopathy play a primary role in the development of infections
in diabetic patients, in particular, the implant-site districts of these
patients respond inadequately to pharmacological treatments
[10,11]. Moreover, the decrease of blood supply increases tissue
necrosis near the implant, reduces the healing process, and
contributes to the development of osteomyelitis [12]. Frequently,
these events lead to the implant loss and to revision surgeries with
high costs. Thus, the reasons for failure of antibiotic treatments
may be due to the severe peripheral vascular disease and
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unsuccessful revascularization. In fact, the reduced peripheral
blood flow in diabetics has been demonstrated to impede the
systemic antibiotics to reach superficial wound and ulcers, thus
limiting the effective control of continued tissue infection by
bacteria [13]. A successful management of peri-prosthetic infec-
tions in diabetics is strictly based on their prevention and novel
therapeutic approaches. The stimulation of local blood supply
could be a therapeutic option to balance the vascular damages
[14,15]. Prostaglandin E1 (PGE1) is a powerful vasodilator able to
increase the peripheral blood perfusion by enhancing the
endothelial function [16,17]. PGE1 is already used for the
treatment of chronic occlusive arterial disease [18] as either
vasodilator or inhibitor of platelet aggregation [15,17,19,20].
PGE1 plays a role to increase skin and muscle blood flow [21] as
well as to generate new blood capillaries in ischemic skeletal
muscles [22]. Moreover, the reduction of infections demonstrates
the efficacy of PGE1 in patients with prior irradiation after
laryngeal surgeries [23]. Others demonstrated that the treatment
of wounds with vasodilators in rats increased the local blood flow
and antibiotic delivery to the site of injury [13]. Therefore, it is
hypothesized that PGE1 administration might decrease the
incidence of surgical infections in diabetic patients. However, the
role of PGE1 in implant-related infections has not yet been
evaluated.
In the present study, we investigated the effects of a PGE1 on
implant-related infections in a diabetic mouse model, as already
described in our previous work [24]. To verify our hypothesis, we
compared data obtained from mice treated with a cephalosporin




The Mario Negri Institute for Pharmacological Research
(IRFMN) Animal Care and Use Committee (IACUC) approved
the whole study (Permit N. 43_2013-B). Animals and their care
were handled in compliance with institutional guidelines as
defined in national (Law 116/92, Authorization n.19/2008-A
issued March 6, 2008, by the Italian Ministry of Health) and
international laws and policies (EEC Council Directive 86/609,
OJ L 358. 1, December 12, 1987; Standards for the Care and Use
of Laboratory Animals - UCLA, U. S. National Research Council,
Statement of Compliance A5023-01, November 6, 1998). The
animals were housed at the Institute’s Animal Care Facilities that
meet international standards; they were regularly checked by a
certified veterinarian responsible for health monitoring, animal
welfare supervision, experimental protocols and procedure revi-
sion.
Experimental design
The effects of the association of a PGE1 vasodilator and a
cephalosporin were tested on a previously validated diabetic
mouse model of staphylococcal orthopaedic implant-related
infection [24].
To this aim, NOD/ShiLtJ mice were assigned to one of three
experimental groups (n = 8 animals in each group):
Group I Sham control (3 ml PBS + Cephalosporin)
Group II Antibiotic treatment (S. aureus 103 CFU/3 ml +
Cephalosporin)
Group III Combined treatment (S. aureus 103 CFU/3 ml +
Cephalosporin + PGE1 vasodilator)
Preparation of S. aureus for inoculation into the joint
space
S. aureus strain ATCC 25923 was used in this study as described
in our recent study [24]. Briefly, bacteria were cultured at 37uC
overnight onto Mannitol Salt Agar (BioMerieux, France) and
incubated into Brain Heart Infusion Broth (BioMerieux) at 37uC
for 16 hours. The bacterial suspension was suspended in PBS to
obtain a 0.5 McFarland turbidity (equal to about 16108 CFU/
mL), then serially diluted with sterile saline solution and counts
were performed to check for bacterial inoculum used for the
experiments.
In vivo surgical procedures
Twenty-four female NOD/ShiLtJ type I diabetic 14 week old
mice (mean body weight 23.361.3 g) (Jackson Laboratory) were
used for this experiment. Blood glucose levels for diabetes were
tested in the NOD/ShiLtJ mice directly by the provider before
delivery. The mice were maintained under specific pathogen-free
conditions and food was provided ad libitum. All procedures on the
animals were performed under a laminar flow hood. The
implantation of the intramedullary nail was performed as
previously described [24,25] and maintained in situ for 28 days.
A bacterial suspension of about 16103 CFU/mouse was injected
in group II and III into the femoral canal after implantation
according to the literature [25,26]. In the sham controls (group I),
sterile PBS was injected as described above. Immediately after
surgery, all animals received a one-shot injection of carprofen
5 mg/kg SC (Rimadyl, Pfizer, Italy) and ceftriaxone 60 mg/kg IM
(Rocephin, Roche, Italy). The cephalosporin bactericidal effect on
S. aureus strain ATCC 25923 was previously tested in vitro.
Additionally, group III was treated intravenously with a PGE1
vasodilator at a dosage of 10 mg/kg (Prostavasin, Schwarz
Pharma, Italy).
The animals were housed in separate cages for 24 h, then
grouped four per cage, and daily clinically monitored. Pain was
controlled with buprenorphine (0.1 mg/kg SC). After 4 weeks, the
mice were euthanized by CO2 inhalation to perform the
investigations on the harvested samples.
Blood collection and analysis
To determine the total white blood cells (WBC) count, blood
samples were collected from the animals’ facial vein (n = 24) on
day 0 and from the left ventricle immediately after sacrifice (day
28) as described by Lovati et al. 2013 [24]. EDTA anti-coagulated
blood samples were used to obtain values of total WBC with an
automatic cell counter for human use (Sysmex XT-1800, Dasit).
Micro-CT imaging and data analysis
To evaluate bone reaction, micro-CT analysis (n = 5 per group)
were performed by two independent examiners on explanted
femurs with an Explore Locus micro-CT scanner (GE Healthcare,
London, Ontario, Canada), without using contrast agents.
Protocols and procedures of micro-CT scan acquisitions were
already described by Lovati et al. 2013 [24]. The images from
each sample were binarized at identical thresholds to allow for
unbiased identification of bone damage and osteolysis.
The image analysis was designed on a volume of interest (VOI)
to evaluate the outer bone volume of the femur to measure any
anatomical changes. Bone mineral density (BMD) was measured
after calibration using a phantom placed in the field of view of the
scanned specimens. The BMD (mg/cc) was measured on the bone
volume designed on the femoral bone by the Micro View image
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viewer (version 2.1.2; GE Healthcare). BMD data were then
normalized on the baseline BMD obtained in the control group I.
Histological analysis
Femoral specimens (n = 4 per group) were fixed in 10%
formalin overnight, then decalcified in Mielodec (Bio-Optica,
Milan, Italy), dehydrated, the metallic implants were removed,
samples were embedded in paraffin, and cut into 5 mm sagittal
sections. After deparaffinization, the slides were stained with
Haematoxylin and Eosin (H&E) and Gram staining to assess the
presence of bacteria, finally analyzed by three independent
examiners using an Olympus IX71 light microscope. The
inflammatory response and infection were both evaluated trough
the periosteal reaction, cortical bone and medullary canal changes
according to the grading score (0 to 3) described in our previous
study [24]. Briefly, the periosteum was analyzed for absence or
presence of reaction; the cortex was mainly analyzed for absence
or presence of polymorpho-nucleated cells, osteoclasts and bone
resorption; and the medullary canal for absence or presence of
polymorpho-nucleated cells and micro- and macroabscesses.
Microbiological analysis
To quantify bacteria within the explanted samples (n = 4 per
group), serial dilutions from sonicated fluids were plated onto
Mueller-Hinton agar plates (Biomerieux, Marcy l’Etoile, France)
and incubated for 16 h at 37uC. Briefly, sterile container
containing explanted samples was filled with 1 ml of sterile saline
and sonicated in an ultrasound bath (VWR, Milan, Italy) for 5 min
with a frequency of 30 kHz and a power output of 300 W at room
temperature. All samples were assayed by serial 10-fold dilution in
sterile saline solution and then plated on solid growth medium.
After incubation of the plates at 37uC for 16 h, colonies of Gram-
positive catalase positive cocci, resembling those of S. aureus, were
tested for coagulase activity with Coagulase Plasma (Remel
Europe Ltd. Dartford, UK) and identified by means of API Staph
assay (BioMerieux, Mercy L’Etoile, France). Positivity to catalase
test consists in the development of gaseous oxygen when the
colony was put in contact with oxygenate water. Coagulase test
results positive when S.aureus colonies in contact with coagulase
plasma, form a visible clot after incubation for 4–6 h at 37uC.
Colonies identified as S. aureus grown on Mueller-Hinton agar
plates were then counted. The detection limit (L. o. D) was#1.300
(Log CFU)/g of bone.
Statistical analysis
Comparisons between groups were analyzed with one-way
analysis of variance (ANOVA) (Instat 2.0; Graphpad Software,
San Diego, CA). Comparisons between groups and time points
were analyzed with two-way ANOVA. When significant differ-
ences were detected, post hoc comparisons of means were
performed using Bonferroni’s procedure. Comparison between
two groups was analyzed with unpaired t-test. All data are
expressed as means 6 standard error (SEM). Values of P,0.05
were considered statistically significant.
Results
Gross appearance and clinical data
The NOD/ShiLtJ mice displayed plasma glucose levels higher
than 130 mg/dl at 14 weeks of age.
Groups I and III showed a slight lameness that solved within few
days after implantation. On the contrary, most of the animals of
group II, except one, developed subcutaneous swelling or abscesses
and a marked lameness persist until the day of explantation. After
two weeks of implantation, one mouse of group II was euthanized
because of the poor conditions and it was replaced by another
animal. Four weeks after implantation, all mice were sacrificed
and femurs were explanted. The gross appearance examination
confirmed the clinical data reported above. Groups I and III did
not show macroscopic signs of infection, while group II showed
macroabscesses of the joint soft tissues and lymph node
enlargement. Signs of infection in group II were related with a
consistent loss of body weight by day 7 post-infection when
compared with group I, which improved the body weight over
time. The mice of group III showed a restricted body weight loss
either at day 7 or at day 14 post-infection compared with group II.
In group III, the body weight increased starting from day 14 and
recovered better than group II at 28 days post-infection.
The histogram in Fig. 1 reports the percentage changes in body
weight versus baseline (day of inoculation/implantation).
Blood analysis
After 28 days, no statistical difference was calculated among the
experimental groups. A mild WBC increase was measured in
group II (3.13%) compared to group I (1.96%) and group III
(2.29%). In particular, no effects of the PGE1 administration on
the WBC count were detected in group III except a lower WBC
decrease in group III compared with group II.
Micro-CT imaging analysis
Micro-CT fluoroscopic examination confirmed the correct
placement of the intramedullary implant within the femoral canal
in all the experimental groups (Fig. 2A).
The qualitative micro-CT analysis showed no damages in the
cortical and endosteal bone either along the diaphysis or femoral
condyles in groups I and III. In group II, the S. aureus infection
established a diffuse bone loss of the femoral metaphysis and
diaphysis associated with the disruption of the endosteal bone, the
decrease of the cortical bone thickness and the enlargement of the
femoral canal (Fig. 2B). The BMD analysis was performed on
values of groups II and III normalized on the BMD mean of group
I, as sham control. Group II displayed a statistically significant
decrease in BMD compared with group III, as shown in the
histogram of Fig. 2C.
Fig. 1. Relative changes in body weight. The histogram shows the
relative changes in body weight in the experimental groups over time.
A significant weight loss was measured in group II versus the control
group I over time. Group III showed a significant body weight loss at
day 14 after implantation compared to group I. Group III recovered
body weight starting from the second week after surgery (two-way
ANOVA, **P,0.01, *P,0.05; n = 8).
doi:10.1371/journal.pone.0094758.g001
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Histological analysis of bones and joints
Group I explants showed a normal aspect of the knee joint,
absence of any signs of infection (Fig. 3A) and normal sized
femoral canal (Fig. 3B). No bone resorption or periosteal reactions
were present in these samples, the cortical bone of the diaphysis
was unaffected and osteocytes appeared small with dense flattened
nuclei (Fig. 3B small box). No bacteria were identified in Gram-
positive staining (Fig. 3C).
In contrast, in group II, joint and bone were affected by
moderate to severe inflammatory changes multifocally extending
to surrounding soft tissues (muscles, tendons and ligaments).
Severe chronic neutrophilic osteomyelitis and arthrosynovitis were
found with multifocal abscesses and pyogranulomas with intrale-
sional bacteria (Fig. 3D). Marked bone resorption of cortical bone
and periosteal reaction were present together with irregularities of
the bone surface facing the bone marrow cavity and presence of
osteoclasts in the endosteal side (Fig. 3E). Numerous intralesional
aggregates of Gram-positive bacteria (cocci) were detected in the
medullary canal as well as in the joint space and within the muscle
fibers (Fig. 3F).
In group III, a partially irregular surface of the articular
cartilage of the knee joint was detected together with mild
inflammatory changes of bone and joint when compared to group
II (Fig. 3G). Diaphysis cortical bone was irregularly thickened and
had moderate to marked signs of bone remodeling (cement lines,
new bone deposition) and overall appeared less dense with
multifocal blood vessels, areas of woven bone and larger osteocytes
compared to unaffected cortical bone of group I (Fig. 3H). Overall,
dispersed Gram-positive bacteria were present in a smaller amount
compared to group II (Fig. 3I).
The histological grading score showed a higher significant
difference in group I compared to group II for all the analyzed
regions, and a significant difference was identified in the medullary
canal of group I compared to group III, as reported in the
histogram of Fig. 4.
Microbiological analysis
After sonication, no bacterial growth was observed in group I
(#1.3 Log CFU/g bone). By contrast, great amounts of S. aureus
bacteria were recovered in the samples of group II with a mean of
5.361.2 (Log CFU)/g bone. A restricted amount of bacteria was
also measured in the samples of group III with a mean of 3.660.9
(Log CFU)/g bone. The histogram in Fig. 5 compares bacterial
counts in all the experimental groups. A statistical difference was
calculated between either group II or III compared with group I.
Despite no statistically differences appeared between group II and
III, the bacterial growth was lower in group III that received the
association of antibiotic and vasodilator.
Fig. 2. Representative micro-CT images and bone mineral density (BMD). A) Representative fluoroscopic image attests the correct
placement of the implant within the femoral canal and the phantom calibration placed in the field of view; B) Magnified representative micro-CT
images of the femurs containing metallic implants in transversal views in all the experimental groups. The images of groups I and III show an intact
cortical bone profile of the whole femur. The image of group II shows a diffuse cortical and endosteal bone loss as signs of osteomyelitis; C) The
histogram shows a high statistically significant difference in the BMD relative decrease of group II versus group III (unpaired t-test, ***P,0.0001;
n = 5).
doi:10.1371/journal.pone.0094758.g002
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Discussion
In diabetic patients, the peripheral blood supply is impaired due
to various degree of angiopathy and microneurovascular dysfunc-
tion [27]. The reduced tissue perfusion may compromise the
delivery of drugs, in particular, in the lower limbs [28,29]. This
impaired vascularization delays the tissue healing after surgery and
increases the rate of implant-related infection despite aggressive
antibiotic therapies [30]. Thus, the priority is to control the risk of
infection by increasing both the vascular supply and the efficacy of
antibiotics.
In this study, we found that the combination of a third
generation cephalosporin with a PGE1 vasodilator improved the
host response to the implant-related S. aureus infection in the
diabetic mouse model, the latter already described in our previous
study [24]. Many studies described the properties of PGE1 to
maintain the blood perfusion, increase angiogenesis and inhibit
platelet aggregation [16,31,32,33]. On this basis, we hypothesized
Fig. 3. Histology of the femurs in the experimental groups (n=4). Figures represent H&E staining in the left and middle panels and Gram-
positive staining in the right panel. Legend: femur (F), tibia (T), cortical bone (CB), and medullary canal (MC). Group I - A) Normal aspect of the knee
joint and absence of signs of infection (Magnification 2X, scale bar 1 mm); B) Absence of inflammatory cells in the medullary canal, of bone resorption
or periosteal reaction (Magnification 4X, scale bar 0.5 mm) and presence of osteocytes within cortical bone lacunae (small box, Magnification 1000X);
C) Absence of Gram-positive bacteria aggregates (Magnification 10X, scale bar 0.2 mm). Group II – D) Abscesses in the knee joint (black arrow) and in
the medullary canal (Magnification 2X, scale bar 1 mm); E) Endosteal bone resorption (#), active osteoclasts (black arrows), marked periosteal
reaction (*) (Magnification 4X, scale bar 0.5 mm) and diffuse enlargement of the medullary canal with osteoclastic resorption in the endosteal side
(small box, Magnification 20X, scale bar 0.1 mm); F) Presence of numerous Gram-positive bacteria aggregates (Magnification 10X, scale bar 0.2 mm;
small box, Magnification 1000X). Group III - G) Irregular surface of the articular cartilage of the knee joint and mild inflammatory changes of bone and
joint (Magnification 2X, scale bar 1 mm); H) Diffuse increase of the vascular network and bone vessel enlargement (#) and areas of bone remodeling
(black arrow) (Magnification 4X, scale bar 0.5 mm); large osteocytes embedded in cortical bone lacunae (small box, Magnification 1000X); I) Mild
presence of dispersed Gram-positive bacteria within the medullary canal (Magnification 10X, scale bar 0.1 mm; small box, Magnification 1000X).
doi:10.1371/journal.pone.0094758.g003
Fig. 4. Histological grading score histogram. The histogram
shows a high statistically significant difference in the histological
grading score in periosteum, cortex and medullary canal of group I
versus group II and a difference in the score of the medullary canal of
group I versus group III (two-way ANOVA, ***P,0.001; *P,0.05; n = 4).
doi:10.1371/journal.pone.0094758.g004
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that the administration of a PGE1 might enhance the antibiotic
delivery in the lower extremities and decrease the bacterial
colonization of the infected site. In the present study, the
intravenous administration of PGE1 has been chosen to avoid
any potential systemic side effects as also suggested by others [22].
The change in body weight is an index of animal welfare,
correlates with behavior in feeding and presence/absence of
diseases [34]. The high statistical difference between group I and
group II assesses the poor condition of the group II treated with
the antibiotic alone, which showed an abnormal behavior in food
intake. Differently, group III, treated with the association of the
antibiotic and vasodilator, was able to regain body weight quicker
and better respect to group II, and it showed no differences when
compared to group I after 28 days from surgery. As reported
elsewhere in diabetic patients, both the impaired bactericidal
activity of polymorphonuclear cells [35–38] and the delayed
hypersensitivity reaction of T-cell function [39,40] explain the
poor response to infection of group II, which showed a very low
body weight increase over time. Differently, in group III, the quick
body weight regain might be related to the efficacy of PGE1 in
promoting the T-cell proliferation and oxygenation, as well as the
response to infection and inflammation, as demonstrated also by
others [41,42]. Furthermore, PGE1 vasodilators have a direct
cytoprotective effect by suppressing the production of proinflam-
matory cytokines [43,44], thus PGE1 indirectly attenuate the
cytotoxic effects of inflammation and improve the host defense
[45]. To strongly support the PGE1 modulatory effect on
inflammation, the serum concentration of proinflammatory
cytokines should be investigated (e.g. C reactive protein). Our
study lacks of this analysis because of the not correctly established
values in mouse serum [24,46].
Despite no statistical difference exits in WBC count among
groups, the relative increase in total WBC count was lower in
group III respect to group II. An increase in WBC count was
expected because PGE1 commonly inhibits the activation and
adhesion of polymorphonuclear neutrophils. However, PGE1
suppresses the release of proinflammatory cytokines from activated
mononuclear cells, cytokines that can cause neutrophilia as
demonstrated in animals [47] and humans [48]. PGE1 has also
an inhibitory effect on granulocyte proliferation [49] and may be
the explanation for our observation.
Ischemia and poor blood supply enhance the bone susceptibility
to microbial invasion. As the infection reaches the medullary
canal, the pressure increases and causes the bacterial extension
into the cortex by bone canals widening into the periosteum and
adjacent soft tissues [50]. In our study, micro-CT detected clear
changes within the cortical bone due to the infection in group II,
confirming the development of a chronic osteomyelitis. In
contrast, group III showed no signs of osteomyelitis and a lower
decrease in BMD compared to group II. These data support the
efficacy of the PGE1 treatment to limit the bacterial extension
within the bone tissue. Moreover, the higher BMD values in group
III confirm the PGE1-mediated anabolic osteogenic response and
bone remodeling, as also demonstrated in other studies [51,52,53].
Histology confirmed the micro-CT results showing evident signs
of infection in group II as compared to the other groups. In
particular, endosteal and intracortical resorption by osteoclasts,
inflammatory cell infiltration, periosteal reaction and bacteria in
the site of implantation in group II were present, as typical signs of
infection as also described in different species by others [38,54,55].
Differently, both in group I and III no or mild signs of chronic
osteomyelitis were detected, respectively, together with normal
sized medullary canal and the presence of active osteoblats.
Moreover, the increased cortical porosity and the bone remodeling
in group III supported the hypothesis that PGE1 stimulates bone
anabolism and subperiosteal bone formation thanks to osteoblast
recruitment, as also described by others [51,56,57]. These
observations are also consistent with observations following a
single systemic administration of PGE1 in rats over a 4-week
period [58,59] and dogs [60]. In further studies, specific
evaluations of vascular network could be useful to confirm the
angiogenic and vasodilation effect of PGE1 on bone.
The microbiological analyses demonstrated a marked bacterial
colonization in group II and a lower presence of bacteria in group
III, despite no significant difference exists. It has been described
that platelet aggregation together with fibrin and blood clots
embeds bacteria at the site of infection withstanding the shear
forces of blood flow [61]. The small difference between group II
and group III with a clear decrease of bacterial count in group III
can be explained by the antiplatelet activity of PGE1 that reduces
the platelet entrapping of bacteria, thus the resistance of
staphylococcal biofilm to antibiotic, as also demonstrated by
others [61,62]. This phenomenon is also supported by the
histological results where the Gram positive staining highlighted
a mild presence of dispersed bacteria within the medullary canal of
group III, differently from bacterial clusters detected in group II.
This effect, together with the increase of peripheral blood flow,
contributes to a better host response to infection.
This study is effectively a single-dose study and the results are
limited to this condition. Further evaluations with a larger group of
animals are also necessary to investigate the immune system
mechanisms, signaling pathways and the vascular changes as well
as different PGE1 dosages and systemic implications. However, the
present study provides some interesting observations that prove the
positive effects of the synergic PGE1-antibiotic treatment on
implant-related S. aureus orthopedic infections in diabetic mice.
Conclusions
In conclusion, we have successfully visualized and quantified
bacterial colonization in diabetic mice treated with the association
of a cephalosporin and a PGE1 vasodilator. We were able to
investigate the infectious processes throughout the course of the
disease in the chronic phases comparing with an untreated sham
control and with animals treated with a standard antibiotic
Fig. 5. Bacterial load in bones of all the experimental groups.
No colonies were detected in group I, the sham control (L.o.D. = limit
of detection). With an infecting dose of 16103 CFU/mouse, a mean of
5.361.2 (Log CFU)/g of bone was found in the explants of group II, with
a statistical difference in respect to group I. A mean of 3.6 6 0.9 (Log
CFU)/g of bone was found in the explants of group III, with a statistical
difference in respect to group I (one-way ANOVA, *P,0.05; **P,0.01;
n = 4).
doi:10.1371/journal.pone.0094758.g005
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therapy. To our knowledge, this is the first study describing the use
of PGE1 as prophylaxis of the osteomyelitis and bacterial
aggregation in diabetic implant-related bacterial infections. This
novel approach, employing a validated diabetic animal model, can
be used to examine in depth the signaling pathways and
mechanisms activated by vasodilators to prevent osteomyelitis
and to evaluate innovative therapeutic strategies for human use.
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